Sign In
NewsRadar

Serentis

Serentis is developing a pipeline of products in areas of unmet medical need. Its initial focus is in the areas of wound care/dermatology and cancer supportive care with additional research programs in fibrotic disease and diabetic complications. Serentis has in-house, low risk discovery capabilities. The company also intends to license near-clinical stage products and technologies.

• Show past press releases
• Edit this company

Contact Information
Address:
 
 

Phone:
Fax:
Web:
Contact:
 
 
23 Cambridge Science Park
Milton Road
Cambridge CB4 0EY
United Kingdom
+44 1223 437064
+44 1223 437063
http://www.serentis-pharma.com
Tim Sharpington
+44 1223 437064

Company Facts
Founded:Jun 2006
Founders:
CEO:Tim Sharpington
CTO or technical lead:Alan Rothaul
CFO or finance director:
Head of Sales:
Head of Marketing:

Stage:
Category:Biotechnology & Healthcare
Sector:Biopharmaceuticals
Employees:
Profitability:
Funding raised:Yes
Funding sought:
Seeking Partnerships:

Non-executive Board Members

  • Allan Marchington, Partner, Apposite Capital
  • Bill Blair, Chief Executive Officer, Adamant Ventures

    Key Customers

    Key Business Partners

    Key Competitors

    Capital Raised
    DateSizeInvestors
    To view this information you must be signed in and subscribed to the online dataservice, sign in here.

    To read more about the Online data service click here

    Public Offerings
    DateTypeExchange
    No public offerings


  • Data


    25,983
    Tech investments
    From our Online Data Service
    16,806
    VC-backed companies
    From our Radar


    Recent Deals


    DATEAMOUNTSECTOR
    Aug 12€2.4MBusiness applications
    Aug 12€0.7MMedical devices
    Aug 12N/AMedical devices
    Aug 9€7.0MSoftware development
    Aug 9€0.3MeLearning
    Aug 9N/AOther Biotechnology & Healthcare
    Aug 7€3.8MDiagnostics

    For information on Europe's most extensive database on technology funding click here!

    Events



    Press Releases


    May 28
    Identiq
    identiq raises $5m seed, launches privacy-first identity validation...

    Apr 29
    Nethone
    nethone raised over $1 million from innovation nest

    Oct 1
    The Link App
    the link app launches version 2.0

    Mar 29
    Addex Therapeutics
    addex sucessfully raises chf40 million in capital increase

    Jan 2
    Urban Jungle
    urban jungle raises 1m in seed funding to build tech-enabled home ...





    About usContact usLegal Information
    Copyright 1999-2019
    Emerging Technology Research Europe Inc. All rights reserved.